Plain-English translation of NCT07633470 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a medication called Zunveyl to see if it is safe and well-tolerated in people with mild to moderate Alzheimer's disease. Researchers also want to understand whether the medication helps reduce behavioral and psychiatric symptoms (like agitation or mood changes) and eases stress for caregivers. The study will last 12 weeks and involve 150 participants.
Alzheimer's disease can cause behavioral problems and psychiatric symptoms that are distressing for both patients and their caregivers. This medication aims to address those symptoms and reduce caregiver strain, which is an important part of care that isn't always well managed.
You likely qualify if…
You likely don't qualify if…
You will take the medication twice daily by mouth for 12 weeks, starting with a lower dose for the first 4 weeks, then a higher dose for the remaining 8 weeks. Your caregiver will attend study visits with you to help track how you're doing, including any changes in behavior, mood, or sleep, and to report on their own stress level. You'll have regular check-ins at the clinic to monitor your safety and how well you're tolerating the medication.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States